YAP1 and metabolic dysfunction-associated steatotic liver disease: Considering that there are no approved drugs for the treatment of nonalcoholic fatty liver disease (NAFLD) or NASH, the present study may reveal some novel opportunities to expand and apply the use of Verteporfin alone or in combination with Rosiglitazone, or other new pan-PPAR agonists displaying a strong PPARγ activity like Lanifibranor [38] for counteracting Yap signaling, which is essential for the activation and maintenance of activated HSCs.